Premium
Long‐acting formulation leading to severe long‐term adverse effects: a case report of fluphenazine and persistent extrapyramidal symptoms
Author(s) -
Omi T.,
Mitsui Y.,
Matsunaga H.
Publication year - 2018
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.12589
Subject(s) - fluphenazine , bromocriptine , extrapyramidal symptoms , medicine , adverse effect , side effect (computer science) , schizophrenia (object oriented programming) , anesthesia , antipsychotic , psychiatry , pharmacology , haloperidol , prolactin , hormone , programming language , computer science , dopamine
Summary What is known and objective Long‐acting formulations are an important therapeutic option for non‐adherent patients with schizophrenia. There is a commonly held view that management of long‐acting formulation‐induced side effects is difficult. Case description We present a patient with schizophrenia who developed acute and persistent extrapyramidal symptoms requiring tracheostomy and long‐term rehabilitation after long‐acting injections of fluphenazine decanoate. Extrapyramidal symptoms improved with declining fluphenazine concentration and antiparkinsonian drug therapy with bromocriptine. What is new and conclusion Long‐acting formulations may lead to severe persistent adverse effects. For preventing fluphenazine‐induced side effects, a possible option might be the antiparkinsonian drug therapy with bromocriptine.